Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.26	$4.19	$2.00 ▼ $4.50	$370.71M	1.18	1.47 million shs	N/A
ETON Eton Pharmaceuticals	$13.96 +3.4%	$16.65	$3.22 ▼ $21.48	$362.04M	1.28	232,667 shs	412,577 shs
VIGL Vigil Neuroscience	$7.95	$5.18	$1.31 ▼ $7.96	$371.04M	3.43	749,659 shs	395,652 shs
ZNTL Zentalis Pharmaceuticals	$1.26 -3.8%	$1.35	$1.01 ▼ $5.44	$94.26M	1.61	1.43 million shs	1.24 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	0.00%	0.00%	+1.67%	+5.45%	+105.80%
ETON Eton Pharmaceuticals	+3.41%	+1.90%	-30.34%	+7.22%	+315.48%
VIGL Vigil Neuroscience	0.00%	+0.38%	+0.89%	+316.23%	+110.32%
ZNTL Zentalis Pharmaceuticals	-3.82%	-8.70%	+5.00%	-30.39%	-69.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	1.9757 of 5 stars	1.2	4.0	4.2	0.6	0.8	0.0
ETON Eton Pharmaceuticals	2.6076 of 5 stars	3.5	3.0	0.0	2.2	1.7	0.6
VIGL Vigil Neuroscience	3.5983 of 5 stars	4.0	5.0	0.0	1.6	2.5	0.6
ZNTL Zentalis Pharmaceuticals	2.1021 of 5 stars	3.3	2.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.72% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	112.51% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	35.85% Upside
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$8.37	564.02% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, CKPT, VIGL, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/22/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$13.00 ➝ $8.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	9,041.59	N/A	N/A	($0.47) per share	-9.06
ETON Eton Pharmaceuticals	$39.01M	9.60	N/A	N/A	$0.94 per share	14.85
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.34	N/A	N/A	$4.73 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	27.92	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$3.13	N/A	N/A	N/A	N/A	-65.48%	-51.05%	8/8/2025 (Estimated)

Latest ZNTL, CKPT, VIGL, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
ETON Eton Pharmaceuticals	1.23	1.97	1.43
VIGL Vigil Neuroscience	N/A	2.97	2.97
ZNTL Zentalis Pharmaceuticals	N/A	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
ETON Eton Pharmaceuticals	27.86%
VIGL Vigil Neuroscience	83.64%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
ETON Eton Pharmaceuticals	16.03%
VIGL Vigil Neuroscience	18.01%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
VIGL Vigil Neuroscience	40	46.67 million	38.27 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	70.59 million	Optionable

ZNTL, CKPT, VIGL, and ETON Headlines

Recent News About These Companies

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

June 26 at 11:20 AM | finance.yahoo.com

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 20, 2025 | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

June 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Holdings Lessened by Woodline Partners LP

May 27, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.comC

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.comA

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.comA

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

March 27, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025 | globenewswire.com

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, CKPT, VIGL, and ETON Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)

As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Eton Pharmaceuticals NASDAQ:ETON

$13.96 +0.46 (+3.41%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$14.36 +0.40 (+2.90%)

As of 04:13 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Vigil Neuroscience NASDAQ:VIGL

$7.95 0.00 (0.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$7.94 0.00 (-0.06%)

As of 04:01 AM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.26 -0.05 (-3.82%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.02 (+1.59%)

As of 06/26/2025 06:16 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time